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Sir,
In response to Blumenthal et al, we would like to further clarify
a few points that have been raised. The main one relates to the
statement made in our paper that ‘there are so far no unconjugated
or ‘naked’ antibodies to carcinoembryonic antigen (CEA) being
used for the treatment of colorectal cancer’ (Conaghan et al, 2008).
Blumenthal et al suggest that this is not correct; however, they fail
to provide evidence to the contrary in their letter. They quote three
published articles in support of their argument. However, the first
one relates to a targeting study using MN-14 (Sharkey et al, 1995).
In the 1980s, radiolabelled murine PR1A3 was also demonstrated
to be highly specific for human colorectal lesions (Granowska et al,
1989). The other two papers present data relating to the use of a
radioconjugate form of MN-14 (Hajjar et al, 2002; Liersch et al,
2005). In the letter from Blumenthal et al, there is reference to
unpublished results with unconjugated MN-14 being used in
patients. It is however difficult to make an informed response
regarding unpublished data. Thus, to our knowledge, the point
made in our paper still holds true: no unconjugated antibody that
targets CEA has been licensed in the treatment of colorectal cancer
in humans by the clinical licensing authorities in the United
Kingdom or United States. This, of course, includes MN-14.
We acknowledge the in vitro and preclinical work that has been
published using MN-14 (labetuzumab), which has been followed
with interest over the years. A reference is actually made to this
antibody in the introduction of our paper (Liersch et al, 2007;
Conaghan et al, 2008). On a broader note, there are in fact over 200
antibodies that are under clinical testing in oncology (Reichert and
Valge-Archer, 2007). Eight of these use CEA as a target, including
T84.66, which, like MN14, have been used in clinical trials as
radioconjugates (Wong et al, 2004; Reichert and Valge-Archer,
2007). Our paper certainly did not try and create an impression
that PR1A3 was the only antibody to target CEA.
It is interesting that 8 out of the 12 antibodies that are currently
licensed for therapy in oncology are unconjugated, and that there
are no conjugated antibodies licensed for therapy in solid tumours
(Carter, 2006; Reichert and Valge-Archer, 2007). This may be
a result of the poor outcomes in clinical trials of radioconjugates
of murine antibodies in the 1980s. Conjugating antibodies to
radioisotopes introduces the problem of bystander damage,
complex technology involved in conjugation and the issue of
adequate radiation delivery into solid tumours (Goldenberg,
2002; Sharkey and Goldenberg, 2005; Reichert and Valge-Archer,
2007).
MN-14 has been used in preclinical studies. However, xenografts
have the inherent problem of being a poor comparative model for
antibody efficacy in humans (Wilkinson et al, 2001). This is based
on two factors, abnormal vascularity of xenografts as well as the
immunodeficient nature of the animals. Furthermore, there are
differences in the murine and human immune system, which
further complicates the matter, thereby raising major concerns
about drawing parallels with what happens in humans. It is
interesting that in the xenograft model, MN-14 was only effective
in the GM-CSF treated group (Blumenthal et al, 2005). This
cytokine is known to stimulate monocytes and promote their
differentiation into macrophages. In mice, this cell type expresses
FcgIV, which is homologous to FcgIII in humans (Nimmerjahn
et al, 2005). A better in vivo model, which may better reflect
antibody targeting, is a spontaneous tumour model in which
immunocompetent MIN mice develop CEA-positive tumours
(Wilkinson et al, 2001). We are currently in an advanced stage
of testing unconjugated murine PR1A3 in this model.
We feel that Blumenthal et al have failed to understand the main
message of our paper, which relates to the importance of immune-
mediated antibody responses. The emergence of immune-based
mechanisms has become increasingly appreciated (Carter, 2006;
Clynes, 2006). The results in our paper show that humanised IgG1
PR1A3 is able to elicit antibody-dependent cellular cytotoxicity
(ADCC) against a range of human colorectal cancer cell lines using
human effector cells (Conaghan et al, 2008). This is in agreement
with the previous findings that MN-14 is able to trigger ADCC of
CEA-positive colorectal cell lines, LoVo and LS174T (Blumenthal
et al, 2005). Our study further defines NK cells as an important
effector cell type in eliciting this response in humans. Significantly,
PR1A3-induced NK-cell-mediated killing of colorectal cancer cells
is not inhibited by free CEA, which is an important characteristic
for any anti-CEA antibody to be successful in vivo. This can be
explained by the specific binding of PR1A3 to membrane-bound
CEA. Previous work has identified the B3-GPI anchor of CEA as
being the epitope of PR1A3 (Durbin et al, 1994; Stewart et al,
1999). The authors feel that this information can be used to further
engineer PR1A3 for maximal clinical effectiveness in humans. Like
Blumenthal et al, we would envisage this happening in partnership
with current chemotherapeutic regimens.
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